__NUXT_JSONP__("/drugs/Vatalanib", (function(a,b){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"212141-54-3",chebiId:"",chemicalFormula:"C20H15ClN4",definition:"An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.",fdaUniiCode:"5DX9U76296",identifier:"C1868",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C1742","C1967"],synonyms:["CGP 79787","CGP-79787","N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine","PTK787","PTK787\u002FZK 222584","VATALANIB",a,"ZK-232934","vatalanib"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FVatalanib",extension:".json",createdAt:b,updatedAt:b}}],fetch:{},mutations:void 0}}("Vatalanib","2021-10-30T13:36:59.303Z")));